Dipharma is a global Contract Development and Manufacturing Organisation (CDMO) and a leading manufacturer of Active Pharmaceutical Ingredients, with more than 500 employees, 4 cGMP plants and commercial offices in Italy, U.S.A. and China.
We put our heart and soul into supporting our customers with a competitive and highly proactive approach, backed by over 70 years of experience in safely handling hazardous chemical processes using state-of-the-art technologies.
As a third-generation family-owned company, we have a long history of stability, commitment and financial solidity.
We know how to deliver on creative innovation and we understand the critical importance of matching timelines, while operating in full respect of international regulations, Intellectual Property and third-party patents.
There are many factors which contribute to our company’s success. In addition to our employees’ knowledge and skills,
these include their value-based, responsible, lawful conduct, in other words: their ethical conduct.
As a company with businesses and operations in several countries, we have a global responsibility to ensure proper conduct and,
for that reason, we have decided to adopt a common Code of Conduct, which outlines the minimum rules to be observed by all our employees.
The story of Dipharma is closely linked to the story of its founder, the chemist and researcher, Mario Biazzi (1897-1974) who, in the mid 1930’s, made significant improvements to the continuous production process of nitroglycerin, making it much more efficient and safer.
His innovation was immediately hailed as a huge success and plants designed on his process were installed in several companies around the world.
While he was perfecting his design, he felt that gaining experience in production could bring significant added-value to his engineering activities, and that is how he decided to start a production company called “Dinamite S.p.A.” with some associates in the North-Eastern part of Italy. Through the experience gained in production, he was able to further improve his technology and bring additional safety to the factory workers. For example, in 1957, he designed the world’s first remote-controlled continuous production plant for nitroglycerin.
Dipharma is committed to ensuring good corporate governance because we believe that good corporate
governance benefits all stakeholders, whether they are customers, suppliers, employees, or shareholders.
The Board of Directors
The Board of Directors of Dipharma Francis S.r.l. is comprised of 5 members.
The Board of Directors is responsible for defining the strategic business guidelines
and monitoring operational management. The Board consists of non-executive
directors with industry expertise and specific technical skills.
MBA, CEO of Dipharma Francis S.r.l. since 2005 to 2019. Chairman of Socorex Holding S.A. and board member of several companies belonging to it.
Chief Executive Officer
Chemist and Chemical Engineer with extensive experience in the global performance Chemicals and Pharmaceutical industries. Senior leadership positions with businesses in Europe, Asia, North and South America.
Economist, professor at Harvard Kennedy School and Luiss, former investment banker at JP Morgan in New York and Mediobanca in Milano.
PhD and MBA, member of Dipharma Francis S.r.l. Board of Directors since 1997. Extensive experience in the Chemical and Pharmaceutical industry through his career as senior management consultant with an international firm.
Our management team is made up of skilled managers with extensive experience in the areas in which they operate.
They combine in-depth industry knowledge with strong leadership and long-term commitment to create innovative competitive solutions for our customers.
& Gen. Services
of Supply Chain
Our management team is composed by skilled managers with an extensive experience in the areas where they operate. They combine in-depth industry knowledge with strong leadership and long-term commitment to create innovative competitive solutions to our customers.